Ligand Pharmaceuticals Incorporated
Last updated September 27, 2026
Organization details
- Legal name
- Ligand Pharmaceuticals Incorporated
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LGND
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000886163
- EIN
- 77-0160744
Board of directors
-
Jason Aryeh · DirectorSince 2023
-
Jason Haas · DirectorSince 2023
-
John L. Lamattina · DirectorSince 2023
-
John W. Kozarich · DirectorSince 2023
-
Martine Zimmermann · DirectorSince 2023
-
Nancy Ryan Gray · DirectorSince 2023
-
Stephen L. Sabba · DirectorSince 2023
-
Todd C. Davis · Director · Chief Executive OfficerSince 2023
Chief executives
Todd C. Davis
· CHIEF EXECUTIVE OFFICER
Dates unknown
Director election results
Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.0%
-
92.7%
-
94.4%
-
95.3%
-
96.5%
-
98.1%
-
98.2%
Board connections
4 of this board's directors also sit on 6 other boards.
- via Martine Zimmermann
- via John L. Lamattina
- via Jason Aryeh
- via Jason Aryeh
- via Todd C. Davis
- via Todd C. Davis
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $33,289,042
- 129 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Martine Zimmermann Director | Shares withheld for tax | −115 | $298.50 | $34,328 |
| Sep 10, 2026 | Martine Zimmermann Director | Open-market sale | −1,200 | $285.00 | $342,000 |
| Sep 3, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −300 | $283.99 | $85,196 |
| Sep 3, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −1,800 | $285.17 | $513,301 |
| Sep 3, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −2,115 | $286.36 | $605,649 |
| Sep 3, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −385 | $287.53 | $110,697 |
| Sep 3, 2026 | Reardon Andrew Officer (CLO & Secretary) | Open-market sale | −400 | $288.98 | $115,592 |
| Aug 12, 2026 | Espinoza Octavio Officer (Chief Financial Officer) | Option exercise | +16,179 | $52.84 | $854,898 |
| Aug 12, 2026 | Jason Haas Director | Option exercise | +6,138 | $51.56 | $316,475 |
| Aug 12, 2026 | Espinoza Octavio Officer (Chief Financial Officer) | Option exercise | +2,074 | $70.04 | $145,263 |
| Aug 12, 2026 | Jason Haas Director | Open-market sale | −7,138 | $292.81 | $2,090,062 |
| Aug 12, 2026 | Espinoza Octavio Officer (Chief Financial Officer) | Option exercise | +2,869 | $55.75 | $159,947 |
| Aug 12, 2026 | Espinoza Octavio Officer (Chief Financial Officer) | Option exercise | +7,171 | $57.22 | $410,325 |
| Aug 12, 2026 | Espinoza Octavio Officer (Chief Financial Officer) | Option exercise | +3,348 | $68.74 | $230,142 |
| Aug 12, 2026 | Espinoza Octavio Officer (Chief Financial Officer) | Open-market sale | −31,641 | $292.07 | $9,241,229 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.